Invetx, an Anterra Capital investment, is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In 2020, the company raised a $15M series A to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma. Partnerships with AbCellera and WuXi Biologics followed shortly after. And in 2022, the company closed a $60M series B from F-Prime, Novo and Casdin.
But before all that, in September of 2019, Occam recruited Bill Brondyke to be the company's first CSO. Brondyke is seasoned drug hunter with 20+ years of experience in developing protein therapeutics for oncology indications, immune-mediated diseases, infectious diseases, rare diseases and reproductive health and contraception.
